Ziegler V R, Kränke B, Soyer P, Aberer W
Klinische Abteilung für Umweltdermatologie und Venerologie, Karl-Franzens-Universität, Graz.
Hautarzt. 1998 Apr;49(4):310-2. doi: 10.1007/s001050050747.
Interferon alpha and gamma have been used to treat several hepatic, hematological and oncological diseases for years. Recently, interferon beta has been introduced as a therapeutic agent in relapsing-remitting multiple sclerosis. A 41-year-old female patient with multiple sclerosis developed non-tender, palm-sized, cutaneous-subcutaneous, reddish infiltrates at the injection sites on her thighs after 8 weeks of treatment with subcutaneous interferon beta injections. Histopathology revealed a perivascular lymphoid infiltrate of the dermis and a subtle lobular lymphoid infiltrate of the subcutis. Interferon beta therapy was discontinued for 4 weeks. With topical corticosteroids, the skin lesions resolved. When subcutaneous injections were resumed at a reduced dose, only erythema around injection sites developed without induration or pain. Slight erythema and swelling at interferon beta injection site are frequent and rare cases of cutaneous necrosis have been described. However, no reports of large, painful, cutaneous-subcutaneous infiltrates after interferon beta therapy have been published.
多年来，α干扰素和γ干扰素一直被用于治疗多种肝脏、血液和肿瘤疾病。最近，β干扰素已被引入用于复发缓解型多发性硬化症的治疗。一名41岁的多发性硬化症女性患者，在接受皮下注射β干扰素治疗8周后，大腿注射部位出现无痛、手掌大小、皮肤-皮下的红色浸润。组织病理学显示真皮血管周围淋巴细胞浸润和皮下组织轻微的小叶性淋巴细胞浸润。β干扰素治疗中断4周。使用外用糖皮质激素后，皮肤病变消退。当以较低剂量恢复皮下注射时，仅注射部位周围出现红斑，无硬结或疼痛。β干扰素注射部位轻微的红斑和肿胀很常见，也有罕见的皮肤坏死病例报道。然而，尚未有关于β干扰素治疗后出现大的、疼痛性皮肤-皮下浸润的报道。
